Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Ryosuke Kitoh"'
Autor:
Yoh-ichiro Iwasa, Moeka Shimizu, Kazuki Matsuura, Kentaro Hori, Ken Hiramatsu, Kenjiro Sugiyama, Yoh Yokota, Tomohiro Kitano, Ryosuke Kitoh, Yutaka Takumi
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract This study aimed to investigate the prognostic value of hematological biomarkers measured before and after treatment in patients with head and neck cancer (HNC). This study reviewed 124 patients with HNC who received chemoradiotherapy. Hemat
Externí odkaz:
https://doaj.org/article/2782415b05cd4cb7a9a79825af78f15d
Publikováno v:
Clinical Case Reports, Vol 11, Iss 6, Pp n/a-n/a (2023)
Key Clinical Message Hematohidrosis is a rare disorder characterized by bloody sweating on the skin without trauma. The ear, nose, and other facial areas are the most commonly affected sites. This study shows usefulness of beta‐blockers in the trea
Externí odkaz:
https://doaj.org/article/ec8e16aea09e4424a601a0359815012b
Autor:
Yoh-ichiro Iwasa, Tomoyuki Nakajima, Kentaro Hori, Yoh Yokota, Ryosuke Kitoh, Takeshi Uehara, Yutaka Takumi
Publikováno v:
Biomolecules, Vol 13, Iss 12, p 1685 (2023)
Although anti-programmed death-1 (PD-1) antibody therapy improves the prognosis in patients with head and neck squamous cell carcinoma (HNSCC), some patients exhibit disease progression even after showing a good response to the treatment initially be
Externí odkaz:
https://doaj.org/article/e60c9b81d9fe4dc89f92168be18dd35c
Autor:
YOH-ICHIRO IWASA, RYOSUKE KITOH, YOH YOKOTA, KENTARO HORI, MARIKO KASUGA, TAKASHI KOBAYASHI, SHINTARO KANDA, YUTAKA TAKUMI
Publikováno v:
Cancer Diagnosis & Prognosis; Mar/Apr2024, Vol. 4 Issue 2, p182-188, 7p
Publikováno v:
Acta Oto-Laryngologica. 143:43-48
Autor:
Keiichiro Koiwai, Dai Hirasawa, Miyu Sugimura, Yuuki Endo, Kai Mizuhata, Hironobu Ina, Ayumu Fukazawa, Ryosuke Kitoh, Hironori Sakai, Yasunari Fujinaga
Publikováno v:
Reports of Practical Oncology and Radiotherapy. 27:954-962
Publikováno v:
Acta Oto-Laryngologica (Supplement). 2020, Vol. 140 Issue 1, p32-39. 8p. 1 Diagram, 5 Charts, 4 Graphs.
Autor:
Yoh-ichiro Iwasa, Yoh Yokota, Ryosuke Kitoh, Kentaro Mori, Keita Tsukada, Nodoka Sekiguchi, Toshirou Fukushima, Takashi Kobayashi, Shintaro Kanda, Yutaka Takumi, Tomonobu Koizumi
Publikováno v:
Oncology. 100:203-211
Background: Nivolumab, a programmed death-1 antibody, is an immune checkpoint inhibitor approved in Japan in March 2017 for the treatment of recurrent or metastatic head and neck cancers (RM-HNCs) after platinum drug administration. This study aimed
Publikováno v:
International Journal of Practical Otolaryngology. :e29-e38
Concurrent chemoradiotherapy (CCRT) is one of the standard treatment strategies for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Prophylactic percutaneous gastrostomy (pPEG) has been reported to be useful for nutritio
Autor:
Yoh-Ichiro Iwasa, Ryosuke Kitoh, Ken Hiramatsu, Kenjiro Sugiyama, Kizuki Watanabe, Rika Yasukawa, Jun Shinagawa, Hiroki Miyajima, Yoh Yokota, Masafumi Kobayashi, Tomohiro Kitano, Kentaro Mori, Yutaka Takumi
Publikováno v:
ORL; journal for oto-rhino-laryngology and its related specialties.
Introduction: Sarcopenia, characterized by low skeletal muscle mass, and the outcome of cancer therapy are closely related based on recent research. This study aimed to evaluate the correlation between skeletal muscle mass and prognosis in head and n